Cardiff Oncology, Inc.CRDFNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank50
3Y CAGR-6.1%
5Y CAGR+5.8%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-6.1%/yr
vs +13.3%/yr prior
5Y CAGR
+5.8%/yr
Recent deceleration
Acceleration
-19.4pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$10.91M-12.6%
2024$12.48M-4.3%
2023$13.04M-1.0%
2022$13.18M+11.3%
2021$11.84M+44.1%
2020$8.22M+42.6%
2019$5.76M-28.0%
2018$8.01M-43.7%
2017$14.23M-38.1%
2016$23.00M-